ACE-031 and Trenbolone Interaction

Monitor
Mechanism-based 46% confidence

ACE-031 and Trenbolone have an interaction requiring monitoring for interaction with 46% confidence. Both ACE-031 and Trenbolone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Half-life: 12-15 days Typical dose: 0.5-3 mg/kg IV every 2 weeks (clinical research doses only) growth hormone, anabolic
actriibmyostatintgf beta androgenicanticoagulantblood pressure raisinghpta suppressive
View full profile

Trenbolone

19-Nor Anabolic-Androgenic Steroid | Potent Recomposition Agent

Trenbolone binds to the androgen receptor with approximately three to five times the affinity of testosterone, making it one of the strongest known AR agonists among anabolic steroids. This exceptional binding affinity drives potent activation of AR-dependent gene transcription, resulting in dramatically enhanced nitrogen retention, protein synthesis, and satellite cell proliferation in skeletal muscle.

Half-life: ~3 days (acetate) Typical dose: 200-400 mg/week anabolic
androgen receptoraromataseigf1ngf androgenicblood pressure raisingcarcinogenic riskcardiotoxic
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
low
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (ACE-031, Trenbolone). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds raise blood pressure (ACE-031, Trenbolone). Monitor BP daily and consider cardiovascular support.
2x 2 HPTA-suppressive compounds (ACE-031, Trenbolone). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (ACE-031, Trenbolone). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (ACE-031, Trenbolone). Monitor accordingly.

Frequently Asked Questions

Can I take ACE-031 with Trenbolone?

Yes, but with caution. Both ACE-031 and Trenbolone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is ACE-031 and Trenbolone safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between ACE-031 and Trenbolone?

Both ACE-031 and Trenbolone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and Trenbolone?

ACE-031 has a half-life of 12-15 days and Trenbolone has a half-life of ~3 days (acetate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: ACE-031 vs Trenbolone

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.